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Abstract
Objective
We sought to investigate various molecular subtypes defined by genomic instability that
may be related to early death and recurrence in colon cancer.
Methods
We sought to investigate various molecular subtypes defined by instability at microsatellites
(MSI), changes in methylation patterns (CpG island methylator phenotype, CIMP) or copy
number variation (CNV) in 8 genes. Stage II-III colon cancers (n = 64) were investigated by
methylation-specific multiplex ligated probe amplification (MS-MLPA). Correlation of CNV,
CIMP and MSI, with mutations in KRAS and BRAFV600E were assessed for overlap in mo-
lecular subtypes and early recurrence risk by uni- and multivariate regression.
Results
The CIMP phenotype occurred in 34% (22/64) and MSI in 27% (16/60) of the tumors, with
noted CIMP/MSI overlap. Among the molecular subtypes, a high CNV phenotype had an
associated odds ratio (OR) for recurrence of 3.2 (95% CI 1.1-9.3; P = 0.026). Losses of
CACNA1G (OR of 2.9, 95% CI 1.4-6.0; P = 0.001), IGF2 (OR of 4.3, 95% CI 1.1-15.8; P =
0.007), CDKN2A (p16) (OR of 2.0, 95% CI 1.1-3.6; P = 0.024), and RUNX3 (OR of 3.4, 95%
CI 1.3-8.7; P = 0.002) were associated with early recurrence, while MSI, CIMP, KRAS or
BRAF V600E mutations were not. The CNV was significantly higher in deceased patients
(CNV in 6 of 8) compared to survivors (CNV in 3 of 8). Only stage and loss of RUNX3 and
CDKN2A were significant in the multivariable risk-model for early recurrence.
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Conclusions
A high copy number variation phenotype is a strong predictor of early recurrence and death,
and may indicate a dose-dependent relationship between genetic instability and outcome.
Loss of tumor suppressors RUNX3 and CDKN2A were related to recurrence-risk and war-
rants further investigation.
Introduction
Colorectal cancer (CRC) is a major global health burden, and develops through the accumula-
tion of genetic and epigenetic changes [1–3]. Genetic instability drives the process from neo-
plastic formation to invasive growth and development of metastasis. Thus, identifying specific
molecular changes and their relationship to clinical endpoints (disease progress, recurrence or,
death) may yield better understanding of the disease process. In CRC, three phenotypically dif-
ferent subgroups have been defined through instability in chromosomes, microsatellites or epi-
genetic alterations [3–5].
Copy number variation (CNV) refers to structural and numerical changes on the chromo-
some level, while microsatellite instability (MSI) occurs when repetitive base pair units have
different number of repetitions in tumor cells compared to corresponding normal cells, which
may produce a shift in the reading frame on the DNA. Last is the CpG island methylator phe-
notype (CIMP), which denotes an aberrant methylation spectrum of the DNA (hypo- or
hypermethylation) that alters gene expression without directly involving genetic modifications
[6–8].
Genetic alterations may involve large structural aberrations at the chromosomal level, and/
or numerical changes at critical regions that can result in tumor promoting gene expression.
For the majority of cancers, extensive chromosomal instabilities (CIN) are observed either as
whole chromosome copy number change through gains and/or losses of chromosome regions,
or as structural changes creating fusion genes [9–11]. Contrary to chromosomal and microsat-
ellite changes or DNAmutations, epigenetic change does not alter the DNA itself but involves
chemical modifications of the DNA such as methylation and histone modifications [12]. Gene
expression is regulated through various mechanisms, including CpG-island methylation, in
which increased methylation on the cytosines in the CpG sites reduces gene expression.
Historically, MSI and CNV (CIN) were regarded as mutually exclusive. However, more re-
cently an overlap between the mentioned phenotypes has been shown [13]. Furthermore, the
CIMP phenotype seems to be associated with the MSI phenotype, but combinations of all phe-
notypes including “triple negatives” have been reported [5]. MSI and BRAF mutation status is
mainly observed in the same samples, and both are suggested to be clinically relevant [14,15].
Patients with tumors of the MSI type are associated with specific clinical, molecular and histo-
pathological features [4,16–19], and have a better prognosis compared to patients with CNV
tumors [20]. Furthermore, the particular tumor location along the colorectal continuum is as-
sociated with site-specific differences in the genetic composition of tumors. For example, rectal
cancers are more prone to CNV type changes and colon cancers (in particular the proximal
part) are more prone to the MSI phenotype [17]. Examination of current staging of CRC,
which is largely based on the lymph node status[21], has recognized shortcomings and discrep-
ancies that are debated [22]. Consequently, several investigators propose alternative molecular
staging strategies [5,23–26], in which groups are based on the presence of CIMP, MSI, KRAS
and BRAF mutations. While this has yet to reach clinical practice, the notion that sub-sites
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within the colon may harbor molecular differences that relate to distinct characteristics is of
importance [17]. Previously we have demonstrated that lymph node numbers may be depen-
dent on sub site location and their related molecular changes, which may be related to clinical
outcome [19,27]. Thus, further exploration of the genomic differences in node-negative and
node-positive colon cancer is of interest to enhance understanding of CRC and related
disease behavior.
Copy number variants (CNVs) are recognized as an important type of genetic variation that
modifies human phenotypes [28,29], including human cancers. Multiplex ligation-dependent
probe amplification (MLPA) is an increasingly common used technique for determining rela-
tive DNA sequence dosage (or copy number variation) [29]. MLPA is a multiplex PCR assay
that utilizes up to 40 probes that are each specific for a different DNA sequence (mainly exons
of a specific gene of interest), to evaluate the relative copy number of each DNA sequence [29].
MLPA can also be used for methylation status determination, copy number analysis in seg-
mentally duplicated regions, expression profiling, and transgene genotyping. MLPA is a cost-
efficient alternative over more labor-intensive and costly methods, such as array comparative
genomic hybridization (aCGH) [29,30]. Moreover, MLPA allows for simultaneous investiga-
tion of methylation status and CNV in tumors, such as previously reported in retinoblastoma
[31].
Thus, the aim of this study was to explore the prevalence of molecular subtypes in stage II
and III colon cancer patients using MLPA to determine the methylation pattern and CNVs in a
defined probe set, and to evaluate its relationship with aggressive disease behavior, defined as
early recurrence (<3 years) after surgery.
Materials and Methods
Patient samples
The study cohort is derived from a consecutive series of 213 stage I-III surgically treated colon
cancers at Stavanger University Hospital during a 4 year period, with details as described previ-
ously [32]. The study was approved by the regional ethics committee (#197.04) and all patients
gave informed consent prior to inclusion. All patients underwent surgery with curative intent.
Patients with lymph node positive (pN+) stage III disease who were physiologically fit (e.g
ECOG performance status 0–1), were offered adjuvant therapy according to national guidelines
at the time.
For the current project, a sub-cohort of patients with colon cancer stage II and III were re-
cruited. Patients who had either a follow-up of at least 36 months at the time of selection (= 3
years, by which time>90% of recurrences occur) or who had died of CRC at commencement
of the current project were eligible. A total of 64 patients fulfilled these criteria and were includ-
ed for MLPA analysis.
Follow up was performed using the 11-digit social security number and access to electronic
patient files for any sign of recurrent disease or a fatal event related to colon cancer. The selec-
tion was based on the information available at 3 years follow up, thus excluding any patient
with shorter follow-up at commencement of the study. Recurrence was defined as any locore-
gional or systemic relapse of the disease at time of follow up.
DNA extraction
DNA from the 64 patients’ tumor samples was extracted and isolated from fresh frozen tissue
using DNeasyMini kit or AllPrep DNA&RNAMini Kit (Qiagen, Hilden, Germany), as described
previously [33].
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Multiplex ligation-dependent probe amplification (MLPA)
The multiplex ligation-dependent probe amplification procedure, using the SALSA MS-MLPA
kit ME042-B1 CIMP probe mix (for detecting methylation status in the promoter regions of 8
different genes; RUNX3, MLH1, NEUROG1, CDKN2A, IGF2, CRABP1, SOCS1 and CAC-
NA1G) as given in Table 1, were performed according to the vendors recommendations
(MRC-Holland, Amsterdam, the Netherlands), and as previously described [34]. As an activat-
ing mutation of BRAFV600E is tightly associated with CIMP positivity [35], a mutation specific
probe is included in the SALSA MS-MLPA kit that detects the V600E (1799T>A) somatic mu-
tation if this is present in the sample.
From all 64 DNA samples, 100 ng DNA was heat-denatured in a total volume of 5 μl Tris-
EDTA buffer, and further performed as recommended by the vendor. Briefly, a mixture of
probe-mix (ME042, MRC-Holland, Amsterdam, the Netherlands) and buffer were added to
the denatured DNA, and probes were allowed to hybridize to the DNA at 60C for 16 hours.
Each sample was divided into two tubes: one of which was ligated, while the other was ligated
and then digested using the methylation-sensitive restriction enzymeHhaI. Both reactions
were then subjected to a PCR reaction using a thermal cycler (GeneAmp 2700, Applied Biosys-
tems, Foster City, CA, USA), and fragment analysis performed on a capillary sequencer (ABI
3130xl, Applied Biosystems, Foster City, CA, USA).
Extracted DNA from normal colonic mucosa was used as a normal reference (n = 12 sam-
ples). Additionally, the colorectal cancer commercial cell-lines Caco-2 and HT-29 were used as
cancer controls (see supporting information, S1 Data file, and S1 and S2 Figs).
The raw data from the analysis were analyzed using Coffalyser.NET (beta version,
MRC-Holland, Amsterdam, the Netherlands).
Definitions
CIMP. Criteria for scoring of CIMP phenotype were more than 20%methylation of a min-
imum of one third of the probes within at least three of the five genes in the Weisenberger
panel[35], as previously described [34].
CNV. For CNV phenotype scoring, all eight genes investigated were used. Copy number
variation (CNV) was used as a proxy for chromosomal instability (CIN) in the study. Loss and
gain were defined using the relative ratio of sample vs reference for a probe were less than 0.7,
or higher than 1.3, respectively. For region analysis, aberration in one or more probes was de-
fined as CNV of the region, and a high CNV phenotype if five or more of the eight regions
(1p36.11, 3p22.2, 5q31.1, 9p21.3, 11p15.5, 15q24.2, 16p13.13 and 17q21.33) were aberrant.
MSI. The MSI phenotype was investigated based on the Bethesda panel of genes using
fragment analysis, as previously described [36]. Furthermore, methylation status of the MLH1
gene using MLPA was used to correlate the methylation status in relation to MSI. In the follow-
ing, MSI status refers to the results from the Bethesda panel, whereas MLH1 investigated by
the MLPA method is referred to as MLH1 methylation.
Mutational analyses
KRAS mutational analyses were performed as previously described in [37]. BRAF mutation
status was determined based on two different methods. One, the MLPA method [34], in which
the BRAF mutation specific probe generated a signal if the V600E mutation was present, and;
second, by using conventional PCR and sequencing analysis, as described previously [38].
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Ethics
Ethical approval for the study was obtained from the Regional Ethics Committee, and all
patients consented to inclusion in the study, as previously described [19].
Statistical analysis
All statistical analyses were performed using the Statistical Package for Social Sciences (IBM
SPSS v. 20). Descriptive data are presented as numbers and rates (%) or medians with inter-
quartile ranges (IQR), if not otherwise stated. Mann-Whitney U-test was used to compare con-
tinuous data between groups when data did not have a normal distribution. Fisher’s exact test
was used for 2x2 tables to compare categorical data, and odds ratio (OR) presented with 95%
confidence interval (95% CI) for significant risk factors. A multiple logistic regression analysis
using both enter and forward modeling was performed to evaluate independent risk-factors for
early recurrence (yes/no) as a dichotomous variable. Gender and age were included in the
model, and models were controlled for CIMP, CNV and MSI as well as KRAS, BRAF mutation
status. Significant factors found on univariate risk-analyses were included in the prediction
model. A Hosmer-Lemeshow Goodness-of-fit test was performed to indicate stability of the
model [39], and contribution to the model variation evaluated by R-square statistics for logistic
regression analysis. All tests were two-sided and a P<0.050 was considered statistically
significant.
Results
Clinical information on recurrence and survival
Of the 64 patients, 58% were females, and median age was 76 years at time of surgery. Clinico-
pathological and molecular data for the included subjects are presented in Table 2. Early recur-
rences were observed in 26 patients (41%), of which 16 had systemic recurrence, 7 had loco-
regional recurrence, and three had both loco-regional and systemic recurrences. Among the 26
patients with recurrent disease, 15 (58%) had died of the disease (23% of the study cohort) at
the time of study inclusion. As expected, 66% of stage III (node positive) patients experienced
recurrence compared to 23% in stage II, for an OR of 6.9 (95% CI 2.2–21.3; p<0.001).
Microsatellite instability and mutational data
The MLPA analyses from tumor samples were technically successful in all 64 included patients,
with regards to the methylation analysis, the chromosomal analysis, and the BRAFV600E muta-
tion analysis. In addition, the KRAS mutation analyses were successful for all 64 patients, and
60 (94%) had a successful MSI status.
The frequency of mutations in KRAS, BRAFV600E and presence of MSI per the number of
methylated genes or per number of chromosomal aberrations is presented in Fig 1A and
1B, respectively.
MSI was found in 16 (27%) of the samples. Methylation of MLH1 was detected in 17 (28%)
samples, and methylation of MLH1 and MSI was concomitantly observed in 14 (23%) of the
patients (p<0.001, Fishers exact test). The MSI and CIMP phenotype, as well as the BRAFV600E
mutation, and MLH1 methylation were significantly statistically associated with right-sided
tumor location (p<0.01, p<0.01, p<0.01 and p = 0.01 for MSI, CIMP, BRAFV600E and MLH1
meth, respectively, using Fishers exact test).
The median number of methylated genes differed significantly between MSI and MSS (mi-
crosatellite stable) samples, (7 and 2, respectively; p<0.01), BRAF wild-type and mutated
Copy Number Variation in Early Cancer Recurrence
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Table 2. Clinicopathological andmolecular features in the patient samples series.
Clinicopathological and
molecular features
All patients
N = 64 (100%)
Alive >3 years
N = 49 (77%)
Died of disease
N = 15 (23%)
Univariate log. Reg,
OR [95% CI]
P-value, Chi-square/
Fisher exact test#
Gender
Female 37 (58) 28 (57) 9 (60) 1.13 [0.35–3.65] 0.845
Male 27 (42) 21 (43) 6 (40)
Age; years, median (range) 76 (30–92) 76.0 (30–92) 77.0 (63–91) -
Stage
II 40 (63) 37 (76) 3 (20) 12.3 [2.97–51.17] <0.001
III 24 (38) 12 (25) 12 (80)
Tumor localization in colon
Right 41 (64) 29 (59) 12 (80) 0.36 [0.09–1.45] 0.220
Left 23 (36) 20 (41) 3 (20)
Tumor size
< 5 cm in diameter 24 (38) 20 (41) 4 (27) 0.53 [0.15–1.89] 0.377
 5 cm in diameter 40 (63) 29 (59) 11 (73)
Recurrence
Present 26 (41) 38 (78) 0 (0) - -
Absent 38 (59) 11 (22) 15 (100)
Adjuvant treatment
No 50 (78) 42 (86) 8 (62) 5.3 [1.44–19.11] 0.008
Yes 14 (22) 7 (14) 7 (38)
KRAS status
wild type 43 (67) 31 (63) 12 (80) 0.43 [0.11–1.73] 0.348
mutated 21 (33) 18 (37) 3 (20)
BRAF status
wild type 49 (77) 39 (80) 10 (67) 0.6 [0.12–3.10] 0.542
mutated 15 (23) 10 (20) 5 (33)
*MSI status
MSS 44 (73) 33 (72) 11 (79) 0.69 [0.16–2.89] 0.740
MSI 16 (27) 13 (28) 3 (21)
MLH1 methylation status
Unmeth 46 (72) 16 (33) 2 (13) 3.15 [0.63–15.67] 0.198
Meth 18 (28) 33 (67) 13 (87)
CIMP status
negative 42 (66) 32 (65) 10 (67) 0.94 [0.28–3.2] 0.923
positive 22 (34) 17 (35) 5 (33)
CNV status
CNV low (= chromosomal stable) 39 (61) 33 (67) 6 (40) 3.1 [0.94–10.20] 0.057
CNV high (= CIN) 25 (39) 16 (33) 9 (60)
*MSI status missing in 4 included patients
#Fisher exact test if less than ﬁve cases in one of the groups
Numbers subject to rounding.
doi:10.1371/journal.pone.0122391.t002
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Fig 1. Distribution of KRAS and BRAFmutations andmicrosatellite instability. (A) Distribution vs number of methylated genes (none had methylation in
all genes, thus 8 not displayed). (B) Distribution vs the number of genes with chromosomal aberrations
doi:10.1371/journal.pone.0122391.g001
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samples (2 and 7; p<0.01), larger tumor size and smaller than 5 cm (3 and 2; p = 0.04), and
male and female sex (2 and 4; p = 0.03).
The BRAFV600E mutation was observed in 15 (23%) samples, 11 within the MSI group, indi-
cating a significant covariation of the two aberrations, (p<0.01). Furthermore, BRAFV600E mu-
tations were significantly associated female sex (p = 0.02), methylation of MLH1 (p<0.01), and
CIMP phenotype (p<0.01). BRAF results were validated by demonstrating BRAF-wt in all
(n = 12) normal samples and in the Caco-2 cell line, but with BRAFV600E mutation present in
the HT-29 cell line, as expected.
Mutations in KRAS were detected in 20 samples (33%), of which eight samples were nega-
tive for CNV, CIMP and MSI. Mutations in both KRAS and BRAF coexisted in two samples,
and in three cases KRAS mutation and MSI were concomitantly observed.
Genome complexity
The samples were categorized for all phenotypes, and grouped based on their combined molec-
ular phenotypes. Overlaps between all phenotypic subgroups were observed. The combined
tumor phenotypes for all patients deceased and living are presented in Table 3, and Fig 1A and
1B and Fig 2A–2C, respectively.
Comparing frequencies of combined phenotypes showed statistically significant difference
for the survivor group compared to the deceased (p = 0.037, binary logistic regression). Of
note, the triple negative and the CNV only phenotype were different between the deceased pa-
tients and the survivors: 13% vs 41% and 40% vs 18%, respectively (Fig 2B and 2C). Isolated
MSI and CNV coexisted in only one sample (2%), while 4 additional patients also had CIMP
(triple positive, 6%). MSI and CIMP were present in the same samples in 10 (16%) cases,
whereas CIMP and CNV were observed for five (8%) samples. The MSI and CIMP phenotypes
most frequently presented in combination with other phenotypes, and as the single phenotype
for only one (2%) and two (3%) cases, respectively. In contrast, the CNV phenotype existed as
the sole phenotype for 15 (23%) of the samples.
Among the different phenotypes, the triple positive and the triple negative were the two
groups displaying the fewest recurrences, 0/4 (0%) and 4/22 (18%), respectively. For the other
phenotypic groups, the recurrences ranged from 40–100%. Furthermore, the frequency of tri-
ple negatives in the patient subgroup without recurrences (18/35) was found to be significantly
different from the recurrence subgroup (4/25), p = 0.007.
Table 3. Frequency of the different phenotypic subgroups.
Phenotypes Study population n = 64 (%) Alive >3 years n = 49 (%) Died of disease n = 15 (%)
MSI only 1 (2) 1 (2) 0 (0)
CNV only 15 (23) 9 (18) 6 (40)
CIMP only 2 (3) 1 (2) 1 (7)
MSI+CNV 1 (2) 0 (0) 1 (7)
MSI+CIMP 10 (16) 8 (16) 2 (13)
CNV+CIMP 5 (8) 3 (6) 2 (13)
Triple negative 22 (34) 20 (41) 2 (13)
Triple positive 4 (6) 4 (8) 0 (0)
ND 4 (6) 3 (6) 1(7)
ND, denotes not dermined
doi:10.1371/journal.pone.0122391.t003
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Aberrations and risk of early recurrence
For the CIMP phenotype, a statistically significant association was observed with female sex
(p = 0.001), right-sided location of the tumor (p = 0.001), and in tumors displaying the MSI
phenotype (p<0.01).
The high CNV phenotype was observed in 25 (39%) of 64 samples, and was associated with
recurrent disease. High CNV phenotype was found in 14 of 25 (56%) recurrences, but only 11
of 39 (28%) of those alive, for an associated odds ratio of 3.2 (95% CI 1.1–9.3; P = 0.026).
Statistical significance was also observed in the number of chromosomally aberrant genes
between deceased patients and survivors (CNV median 6, IQR 3–7 vs CNVmedian 3, IQR
1–5; P = 0.001),Fig 2A.
There were more aberrations in the early recurrence group overall when separately compar-
ing the number of aberrant probes for each gene between patients with no recurrence and
those with early recurrence, Fig 3. The difference in number of aberrant positions between sur-
vivors and deceased for CDKN2A, IGF2 and CACNA1G was statistically significant, Fig 4B.
When using the dichotomized status (aberrant/normal) for each gene, aberrations in CAC-
NA1G (p = 0.007), CDKN2A (p = 0.003) and RUNX3 (p = 0.032) were significantly associated
with disease related death.
More specifically, loss of CACNA1G conferred an OR of 2.9 (95% CI 1.4–6.0; P = 0.001) for
recurrence, as 18 of 30 (60%) of patients with this CNV recurred compared to only 7 of 34
(21%) with normal status. Loss of IGF2 was associated with an OR of 4.3 (95% CI 1.1–15.8;
P = 0.007), as 23 of 47 (49%) recurred, compared to 2 of 17 (12%) with normal status. Loss of
CDKN2A had an OR of 2.0 (95% CI 1.1–3.6; P = 0.024), with 61% recurrence for those with
loss, compared to 30% for those with normal status. Finally, loss of RUNX3 was associated
with an OR of 3.4 (95% CI 1.3–8.7; P = 0.002) with recurrence occurring in 64% with loss com-
pared to 16% of those with normal status.
There were no significant difference between stage II and III regarding the frequency of the
three different molecular phenotypes (MSI, CNV and CIMP), and the combined phenotypes,
as well as BRAF and KRAS mutations. Inactivation of CACNA1G due to methylation was ob-
served most frequently in BRAF mutated and MSI tumors (p0.01), and most frequently in tu-
mors located in the proximal colon.
Multivariable modeling of early-recurrence risk
In a multiple logistic regression model with the variables CNV, CIMP, MSI, KRAS, BRAF,
stage, tumor localization and gender, the only variable that was retained in the model for recur-
rence risk was stage. Analyzing cancer-death as an outcome using the same variables, CNV sta-
tus was included together with stage in the model, but with wide confidence intervals for the
adjusted ORs.
Introducing the independent gene aberrations significantly associated with early recurrence
risk (losses of RUNX3, CDKNA2A, CACNA1G and IGF2) and controlling for the above men-
tioned molecular subtypes and age, gender, stage and tumor location, revealed a final model
that included only RUNX3 and CDKN2A together with stage as predictors of early recurrence
(Table 4). A Hosmer-Lemeshow Goodness of fit test (Chi-square 3.844; p = 0.572) indicated a
robust model. The R-square statistics (Cox&Snell and Nagelkerke) was reported between 0.316
Fig 2. Venn diagrams illustrating the frequencies of the molecular phenotypes. (A) The total study population, (B) Patients alive with no recurrence
(surviving for>3 years), (C) Patients with early recurrence or death (within 3 years after surgery).
doi:10.1371/journal.pone.0122391.g002
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Fig 3. Copy number variation (CNV) in relation to clinical outcome. (A) Boxplot showing the number of
aberrant genes in deceased patients (right) and survivors (left). (B) Boxplot showing the number of aberrant
chromosome positions in each of the genes studied, in recurrent (or deceased) patients (right) and patients
with no early recurrence (left).
doi:10.1371/journal.pone.0122391.g003
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and 0.427, indicating that the model explained between 31.6% and 42.7% of variation in the
risk estimation.
Discussion
In the current study, we investigated the interaction and overlap between molecular subtypes
in colon cancer with development of early recurrence after surgery. As described, there is over-
lap between several molecular features that complicates the clear distinction between groups
Fig 4. Bar chart illustrating the percentage of aberrant patient samples per probe.Red bars represent lost regions and blue bars represent gains. Lines
illustrating gains and losses in patients alive>3 years (blue and purple, respectively), and patients deceased of disease (green and red, respectively)
doi:10.1371/journal.pone.0122391.g004
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for molecular and clinical relevance. Using MLPA for a panel of 8 genes, we demonstrated that
the gene dosage effect of methylation and chromosomal aberrations is in part associated with
molecular signature and presence of mutations, and is also related to risk of early recurrence.
In addition to stage III, early recurrence was associated with loss of RUNX3 and CDKN2A,
both of which are known tumor suppressor genes in CRC and previously reported to be associ-
ated with clinical outcome in CRC [40–43]. This may potentially be used as prognostic infor-
mation in addition to the current TNM-staging system to avoid misclassification, as lymph
node status (definition of node negative or positive disease) has several shortcomings, which
has been discussed in detail elsewhere [21,22]. Also, defining patients at risk for early recur-
rence may facilitate targeted and better tailored surveillance after surgery[44].
For colorectal cancer, three broad molecular phenotypes are described, including CNV, MSI
and epigenetic changes [3,7,8]. Investigators have proposed distinct classification of 3, 4 and 5
groups in the past [14,24–26], but none has yet reached clinical practice. The extent of overlap
between these phenotypic groups has been investigated [5,14,16,25,45–47], but the clinical im-
plications of the molecular phenotypes are so far vague. The use of different methodology, defi-
nitions, scoring criteria, and differences in the type of patient material investigated make
comparisons difficult, which is underscored by the overlap found in this study. Additionally,
and as we have documented recently, the use of different criteria for CIMP-status may differs
with the use of included genes and probes [34], and thus generates different results between
studies, which hinders comparison.
In total, MSI was observed in 27% of the colon cancers. This is in line with other studies in
which rectal cancers are not included, as colon cancers have a higher prevalence of MSI. Both
the MSI phenotype and MLH1 methylation were found in 14/60 samples (23%). Two samples
displayed the MSI phenotype without MLH1 methylation, and three samples showed MLH1
methylation without MSI. The extensive overlap between these features supports the fact that
MLH1 inactivation causes MSI. However, a discrepancy in MLH1 methylation and MSI has
also been observed by others [48,49], and illustrates that several DNAmismatch repair genes
including MLH1 cause MSI. On the contrary, methylation of MLH1 does not necessarily lead
to impairment of the mismatch repair machinery.
Table 4. Multivariable model for early risk of recurrence.
Factor B S.E. Wald Df P OR OR 95% C.I. (Lower/Upper)
Step1a Stage II vs III 1.764 .582 9.189 1 .002 5.833 1.865/18.245
Constant -.253 .291 .758 1 .384 .776
Step2b Stage II vs III 1.808 .634 8.133 1 .004 6.099 1.760/21.131
Loss_RUNX3 1.770 .699 6.405 1 .011 5.871 1.491/23.126
Constant -.550 .345 2.538 1 .111 .577
Step 3c Stage II vs III 2.013 .692 8.467 1 .004 7.489 1.929/29.067
Loss_CDKN2A 1.622 .738 4.831 1 .028 5.063 1.192/21.510
Loss_RUNX3 1.801 .725 6.175 1 .013 6.053 1.463/25.045
Constant -.214 .384 .310 1 .577 .808
Variables in the Equation
a Variable(s) entered on step 1: Stage_II_III.
b Variable(s) entered on step 2: Loss_RUNX3.
c Variable(s) entered on step 3: Loss_CDKN2A.
doi:10.1371/journal.pone.0122391.t004
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The BRAFV600E mutation status was predicted using both conventional DNA sequencing
and MLPA with specific probes for the point mutation. Both results were in 100% concor-
dance, and show the MLPA methodology to be reliable.
Mutations in BRAFV600E and KRAS were originally reported as mutually exclusive [50]. A
double activation of the MAPK pathway has been suggested to lead to differentiation and cell
senescence, rather than growth promotion as is the result of a single mutation [51]. However,
for two patients in our sample series, the mutations were found to coexist, albeit with numbers
too low to allow for any clinical interpretation.
Patients with early recurrence showed numerically more chromosomal aberrations (Figs 3
and 4). This supports the suggestion that CNV could predict a worse prognosis [52], as indicat-
ed by a high CNV in the current study. For stage II patients, the numerical difference in chro-
mosomal aberrations between recurrence and no recurrence was statistically significant
(p = 0.022), as was the numerical difference for deceased or surviving patients (p = 0.007). This
difference could not be observed for stage III patients. As stage II patients are normally treated
with surgery alone, this could be used as a prognostic marker for recurrence, and potentially as
an aid when selecting stage II patients who would benefit from adjuvant therapy. However, the
results should be interpreted with caution based on the sample size and validated in larger pa-
tient series to be confirmed.
One interesting observation is that chromosomal aberrations, rather than methylation itself,
of genes included in the CIMP panel seems to be most important for clinical outcome of dis-
ease. This implies that the genes in the CIMP panel have tumor suppressor activity, and that
their mechanistic function is important with regards to colon cancer, and not only for methyla-
tion. Indeed, both RUNX3 and CDKN2A (also known as p16) are known tumor suppressor
genes. Aberrations in RUNX3 have been reported as an early event in colorectal cancer pro-
gression[40]. The normal activity of the CDKN2A (also known as p16) gene is as a tumor sup-
pressor, preventing uncontrolled cell proliferation by initiating cell cycle arrest and apoptosis.
The prognostic significance of CDKN2A inactivation in colorectal cancer has been studied, but
no clear associations has been found [43]. Further, normal function of CACNA1G affects cell
proliferation and apoptosis, and disturbing this calcium signaling might be important in can-
cer, as these processes guide further progress in cellular life. This indicates its instrumental im-
portance, and that nonfunctional CACNA1G will switch the cells over to a more aggressive
function [53]. Also, the protein hormone IGF2 is involved in development and growth of the
cell, and is involved in carcinogenesis [54,55].
When investigating the number of methylated positions, there was significantly more meth-
ylation in MSI tumors compared to MSS, and in BRAF mutated samples compared to wild-
type. This is most probably because methylation of CRC-critical genes causes MSI in non-famil-
ial colorectal cancer [56]. However, the number of methylated positions was also statistically sig-
nificant larger in large tumors compared to smaller, and in tumors from females compared
to males.
Conclusions
Stage II-III colon cancer patients who experience early cancer recurrences after surgery had sig-
nificantly more chromosomal aberrations (median 6 vs. median of 3 for living patients) than
patients with no evidence of disease at 3 years follow up. Loss of the tumor suppressor genes
RUNX3 and CDKN2A (p16) appear to hold important clinical information in addition to
node-status (stage III; node positive disease). The additional role of CACNA1G and IGF2 war-
rants further studies, both to investigate tumor-regulating mechanisms and to confirm the clin-
ical role in larger patient samples.
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S1 Fig. Illustration of rawdata from copy number analyses of normal and control samples.
Cut off for scoring of gain and loss is indicated.
(TIF)
S2 Fig. Illustration of rawdata from methylation analyses of normal and control samples.
Cut off for scoring of methylation is indicated.
(TIF)
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